Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas

Liposarcoma

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Patient Reported Outcome Measures (PROMs) With Trabectedin Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma